{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:42:06Z","timestamp":1789717326020,"version":"4.0.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,5,18]],"date-time":"2011-05-18T00:00:00Z","timestamp":1305676800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Weekly docetaxel has occasionally been used in the neoadjuvant to downstage breast cancer to reduce toxicity and possibly enhance quality of life. However, no studies have compared the standard three weekly regimen to the weekly regimen in terms of quality of life. The primary aim of our study was to compare the effects on QoL of weekly versus 3-weekly sequential neoadjuvant docetaxel. Secondary aims were to determine the clinical and pathological responses, incidence of Breast Conserving Surgery (BCS), Disease Free Survival (DFS) and Overall Survival (OS).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Eighty-nine patients receiving four cycles of doxorubicin and cyclophosphamide were randomised to receive twelve cycles of weekly docetaxel (33 mg\/m<jats:sup>2<\/jats:sup>) or four cycles of 3-weekly docetaxel (100 mg\/m<jats:sup>2<\/jats:sup>). The Functional Assessment of Cancer Therapy-Breast and psychosocial questionnaires were completed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>At a median follow-up of 71.5 months, there was no difference in the Trial Outcome Index scores between treatment groups. During weekly docetaxel, patients experienced less constipation, nail problems, neuropathy, tiredness, distress, depressed mood, and unhappiness. There were no differences in overall clinical response (93% vs. 90%), pathological complete response (20% vs. 27%), and breast-conserving surgery (BCS) rates (49% vs. 42%). Disease-free survival and overall survival were similar between treatment groups.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Weekly docetaxel is well-tolerated and has less distressing side-effects, without compromising therapeutic responses, Breast Conserving Surgery (BCS) or survival outcomes in the neoadjuvant setting.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>ISRCTN: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.controlled-trials.com\/ISRCTN09184069\" ext-link-type=\"uri\">ISRCTN09184069<\/jats:ext-link>\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1471-2407-11-179","type":"journal-article","created":{"date-parts":[[2011,5,19]],"date-time":"2011-05-19T18:46:50Z","timestamp":1305830810000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer"],"prefix":"10.1186","volume":"11","author":[{"given":"Leslie G","family":"Walker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M","family":"Eremin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark M","family":"Aloysius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wichai","family":"Vassanasiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary B","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"El-Sheemy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ged","family":"Cowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Beer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srila","family":"Samphao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Wiseman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jibril A","family":"Jibril","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Valerio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mujahid","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald W","family":"Thorpe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Baria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleg","family":"Eremin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,5,18]]},"reference":[{"issue":"6 Suppl","key":"2673_CR1","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/1097-0142(19900915)66:14+<1387::AID-CNCR2820661414>3.0.CO;2-I","volume":"66","author":"GN Hortobagyi","year":"1990","unstructured":"Hortobagyi GN: Comprehensive management of locally advanced breast cancer. Cancer. 1990, 66 (6 Suppl): 1387-1391.","journal-title":"Cancer"},{"issue":"1","key":"2673_CR2","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1200\/JCO.1998.16.1.93","volume":"16","author":"G Bonadonna","year":"1998","unstructured":"Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M, Zambetti M: Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol. 1998, 16 (1): 93-100.","journal-title":"J Clin Oncol"},{"issue":"12","key":"2673_CR3","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1200\/JCO.2005.02.6187","volume":"24","author":"M Kaufmann","year":"2006","unstructured":"Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, Valagussa P, Blohmer JU, Eiermann W, Jackesz R, Jonat W, et al: Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol. 2006, 24 (12): 1940-1949. 10.1200\/JCO.2005.02.6187.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2673_CR4","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S0305-7372(96)90025-0","volume":"22","author":"PA Ellis","year":"1996","unstructured":"Ellis PA, Smith IE: Primary chemotherapy for early breast cancer. Cancer Treat Rev. 1996, 22 (6): 437-450. 10.1016\/S0305-7372(96)90025-0.","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"2673_CR5","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1200\/JCO.1998.16.8.2672","volume":"16","author":"B Fisher","year":"1998","unstructured":"Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998, 16 (8): 2672-2685.","journal-title":"J Clin Oncol"},{"issue":"13","key":"2673_CR6","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1200\/JCO.2005.04.1665","volume":"24","author":"HD Bear","year":"2006","unstructured":"Bear HD, Anderson S, Smith RE, Geyer CE, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, et al: Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006, 24 (13): 2019-2027. 10.1200\/JCO.2005.04.1665.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2673_CR7","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1093\/jnci\/dji021","volume":"97","author":"D Mauri","year":"2005","unstructured":"Mauri D, Pavlidis N, Ioannidis JP: Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005, 97 (3): 188-194. 10.1093\/jnci\/dji021.","journal-title":"J Natl Cancer Inst"},{"issue":"22","key":"2673_CR8","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.1200\/JCO.2001.19.22.4224","volume":"19","author":"JA van der Hage","year":"2001","unstructured":"van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L: Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001, 19 (22): 4224-4237.","journal-title":"J Clin Oncol"},{"issue":"13","key":"2673_CR9","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1200\/JCO.2005.06.156","volume":"23","author":"TR Evans","year":"2005","unstructured":"Evans TR, Yellowlees A, Foster E, Earl H, Cameron DA, Hutcheon AW, Coleman RE, Perren T, Gallagher CJ, Quigley M, et al: Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an anglo-celtic cooperative oncology group study. J Clin Oncol. 2005, 23 (13): 2988-2995. 10.1200\/JCO.2005.06.156.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2673_CR10","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1200\/JCO.20.6.1456","volume":"20","author":"IC Smith","year":"2002","unstructured":"Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK, et al: Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002, 20 (6): 1456-1466. 10.1200\/JCO.20.6.1456.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2673_CR11","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.1999.17.7.1999","volume":"17","author":"G von Minckwitz","year":"1999","unstructured":"von Minckwitz G, Costa SD, Eiermann W, Blohmer JU, Tulusan AH, Jackisch C, Kaufmann M: Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol. 1999, 17 (7): 1999-2005.","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"2673_CR12","first-page":"S16","volume":"9","author":"L Walker","year":"1998","unstructured":"Walker L, Anderson J, Heys S: Quality of life during primary chemotherapy.: randomised controlled trial of CVAP and docetaxel. Annals of Oncology. 1998, 9 (Suppl 4): S16-","journal-title":"Annals of Oncology"},{"issue":"1-2","key":"2673_CR13","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/sj.bjc.6690349","volume":"80","author":"LG Walker","year":"1999","unstructured":"Walker LG, Walker MB, Ogston K, Heys SD, Ah-See AK, Miller ID, Hutcheon AW, Sarkar TK, Eremin O: Psychological, clinical and pathological effects of relaxation training and guided imagery during primary chemotherapy. Br J Cancer. 1999, 80 (1-2): 262-268. 10.1038\/sj.bjc.6690349.","journal-title":"Br J Cancer"},{"issue":"6","key":"2673_CR14","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1200\/JCO.2000.18.6.1212","volume":"18","author":"HJ Burstein","year":"2000","unstructured":"Burstein HJ, Manola J, Younger J, Parker LM, Bunnell CA, Scheib R, Matulonis UA, Garber JE, Clarke KD, Shulman LN, et al: Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol. 2000, 18 (6): 1212-1219.","journal-title":"J Clin Oncol"},{"issue":"15","key":"2673_CR15","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1200\/JCO.2001.19.15.3500","volume":"19","author":"JD Hainsworth","year":"2001","unstructured":"Hainsworth JD, Burris HA, Yardley DA, Bradof JE, Grimaldi M, Kalman LA, Sullivan T, Baker M, Erland JB, Greco FA: Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol. 2001, 19 (15): 3500-3505.","journal-title":"J Clin Oncol"},{"issue":"9","key":"2673_CR16","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1093\/annonc\/mdh349","volume":"15","author":"J Tabernero","year":"2004","unstructured":"Tabernero J, Climent MA, Lluch A, Albanell J, Vermorken JB, Barnadas A, Anton A, Laurent C, Mayordomo JI, Estaun N, et al: A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol. 2004, 15 (9): 1358-1365. 10.1093\/annonc\/mdh349.","journal-title":"Ann Oncol"},{"issue":"2","key":"2673_CR17","first-page":"686","volume":"9","author":"LG Estevez","year":"2003","unstructured":"Estevez LG, Cuevas JM, Anton A, Florian J, Lopez-Vega JM, Velasco A, Lobo F, Herrero A, Fortes J: Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study. Clin Cancer Res. 2003, 9 (2): 686-692.","journal-title":"Clin Cancer Res"},{"issue":"25","key":"2673_CR18","doi-asserted-by":"publisher","first-page":"5983","DOI":"10.1200\/JCO.2005.06.232","volume":"23","author":"MC Green","year":"2005","unstructured":"Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, et al: Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol. 2005, 23 (25): 5983-5992. 10.1200\/JCO.2005.06.232.","journal-title":"J Clin Oncol"},{"issue":"16","key":"2673_CR19","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMoa0707056","volume":"358","author":"JA Sparano","year":"2008","unstructured":"Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW, Wood WC, Davidson NE: Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008, 358 (16): 1663-1671. 10.1056\/NEJMoa0707056.","journal-title":"N Engl J Med"},{"issue":"3","key":"2673_CR20","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.1997.15.3.974","volume":"15","author":"MJ Brady","year":"1997","unstructured":"Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, Deasy S, Cobleigh M, Shiomoto G: Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol. 1997, 15 (3): 974-986.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2673_CR21","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/bjc.1990.434","volume":"62","author":"JC de Haes","year":"1990","unstructured":"de Haes JC, van Knippenberg FC, Neijt JP: Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br J Cancer. 1990, 62 (6): 1034-1038. 10.1038\/bjc.1990.434.","journal-title":"Br J Cancer"},{"key":"2673_CR22","first-page":"359","volume":"9","author":"J Anderson","year":"2000","unstructured":"Anderson J, Walker M, Walker L: The Mood Rating Scale: a brief, acceptable, reliable and valid state measure of normal mood. Psycho-oncology. 2000, 9: 359-","journal-title":"Psycho-oncology"},{"issue":"2","key":"2673_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0022-3999(01)00296-3","volume":"52","author":"I Bjelland","year":"2002","unstructured":"Bjelland I, Dahl AA, Haug TT, Neckelmann D: The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J Psychosom Res. 2002, 52 (2): 69-77. 10.1016\/S0022-3999(01)00296-3.","journal-title":"J Psychosom Res"},{"issue":"6","key":"2673_CR24","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983, 67 (6): 361-370. 10.1111\/j.1600-0447.1983.tb09716.x.","journal-title":"Acta Psychiatr Scand"},{"issue":"3","key":"2673_CR25","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/bjc.1977.42","volume":"35","author":"JL Hayward","year":"1977","unstructured":"Hayward JL, Carbone PP, Heusen JC, Kumaoka S, Segaloff A, Rubens RD: Assessment of response to therapy in advanced breast cancer. Br J Cancer. 1977, 35 (3): 292-298. 10.1038\/bjc.1977.42.","journal-title":"Br J Cancer"},{"issue":"Suppl 1","key":"2673_CR26","first-page":"S25","volume":"12","author":"IC Smith","year":"2001","unstructured":"Smith IC, Miller ID: Issues involved in research into the neoadjuvant treatment of breast cancer. Anticancer Drugs. 2001, 12 (Suppl 1): S25-29.","journal-title":"Anticancer Drugs"},{"issue":"3","key":"2673_CR27","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1200\/JCO.2000.18.3.623","volume":"18","author":"P Bonomi","year":"2000","unstructured":"Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D: Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2000, 18 (3): 623-631.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2673_CR28","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1023\/A:1015276414526","volume":"11","author":"D Cella","year":"2002","unstructured":"Cella D, Hahn EA, Dineen K: Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res. 2002, 11 (3): 207-221. 10.1023\/A:1015276414526.","journal-title":"Qual Life Res"},{"issue":"9","key":"2673_CR29","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/j.jclinepi.2004.01.012","volume":"57","author":"DT Eton","year":"2004","unstructured":"Eton DT, Cella D, Yost KJ, Yount SE, Peterman AH, Neuberg DS, Sledge GW, Wood WC: A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol. 2004, 57 (9): 898-910. 10.1016\/j.jclinepi.2004.01.012.","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"2673_CR30","first-page":"498","volume":"44","author":"YH Chan","year":"2003","unstructured":"Chan YH: Biostatistics 103: qualitative data - tests of independence. Singapore Med J. 2003, 44 (10): 498-503.","journal-title":"Singapore Med J"},{"key":"2673_CR31","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"E Kaplan","year":"1958","unstructured":"Kaplan E, Meier P: Nonparametric estimation from incomplete observations. Journal of the American Statistical Association. 1958, 53: 457-481. 10.2307\/2281868.","journal-title":"Journal of the American Statistical Association"},{"key":"2673_CR32","volume-title":"Cancer Treat Rev","author":"D Mauri","year":"2009","unstructured":"Mauri D, Kamposioras K, Tsali L, Bristianou M, Valachis A, Karathanasi I, Georgiou C, Polyzos NP: Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis. Cancer Treat Rev. 2009"},{"issue":"3","key":"2673_CR33","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1056\/NEJMc081136","volume":"359","author":"S Aksoy","year":"2008","unstructured":"Aksoy S, Dizdar O, Altundag K: Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008, 359 (3): 310-author reply 310-311","journal-title":"N Engl J Med"},{"key":"2673_CR34","volume-title":"Eur J Cancer","author":"CP Schroder","year":"2011","unstructured":"Schroder CP, de Munck L, Westermann AM, Smit WM, Creemers GJ, de Graaf H, Stouthard JM, van Deijk G, Erjavec Z, van Bochove A, et al: Weekly docetaxel in metastatic breast cancer patients: No superior benefits compared to three-weekly docetaxel. Eur J Cancer. 2011"},{"issue":"1","key":"2673_CR35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ctrv.2009.10.006","volume":"36","author":"D Mauri","year":"2010","unstructured":"Mauri D, Kamposioras K, Tsali L, Bristianou M, Valachis A, Karathanasi I, Georgiou C, Polyzos NP: Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis. Cancer Treat Rev. 2010, 36 (1): 69-74. 10.1016\/j.ctrv.2009.10.006.","journal-title":"Cancer Treat Rev"},{"issue":"10","key":"2673_CR36","doi-asserted-by":"publisher","first-page":"3249","DOI":"10.1158\/1078-0432.CCR-03-0133","volume":"10","author":"LG Estevez","year":"2004","unstructured":"Estevez LG, Gradishar WJ: Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer. Clin Cancer Res. 2004, 10 (10): 3249-3261. 10.1158\/1078-0432.CCR-03-0133.","journal-title":"Clin Cancer Res"},{"issue":"22","key":"2673_CR37","doi-asserted-by":"publisher","first-page":"3619","DOI":"10.1200\/JCO.2005.04.4453","volume":"24","author":"B Esmaeli","year":"2006","unstructured":"Esmaeli B, Amin S, Valero V, Adinin R, Arbuckle R, Banay R, Do KA, Rivera E: Prospective study of incidence and severity of epiphora and canalicular stenosis in patients with metastatic breast cancer receiving docetaxel. J Clin Oncol. 2006, 24 (22): 3619-3622. 10.1200\/JCO.2005.04.4453.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2673_CR38","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/S0161-6420(02)00989-2","volume":"109","author":"B Esmaeli","year":"2002","unstructured":"Esmaeli B, Hortobagyi GN, Esteva FJ, Booser D, Ahmadi MA, Rivera E, Arbuckle R, Delpassand E, Guerra L, Valero V: Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer. Ophthalmology. 2002, 109 (6): 1188-1191. 10.1016\/S0161-6420(02)00989-2.","journal-title":"Ophthalmology"},{"issue":"5","key":"2673_CR39","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/S0161-6420(00)00640-0","volume":"108","author":"B Esmaeli","year":"2001","unstructured":"Esmaeli B, Valero V, Ahmadi MA, Booser D: Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect. Ophthalmology. 2001, 108 (5): 994-995. 10.1016\/S0161-6420(00)00640-0.","journal-title":"Ophthalmology"},{"issue":"Suppl 2","key":"2673_CR40","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.3816\/CBC.2002.s.015","volume":"3","author":"SD Heys","year":"2002","unstructured":"Heys SD, Hutcheon AW, Sarkar TK, Ogston KN, Miller ID, Payne S, Smith I, Walker LG, Eremin O: Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer. 2002, 3 (Suppl 2): S69-74.","journal-title":"Clin Breast Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-11-179.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-11-179\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-11-179","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-11-179.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T20:13:05Z","timestamp":1630613585000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-11-179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,18]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["2673"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-11-179","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,18]]},"assertion":[{"value":"23 April 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"179"}}